ArticleMedical science monitor : international medical journal of experimental and clinical research2018
Propofol Promotes Activity and Tumor-Killing Ability of Natural Killer Cells in Peripheral Blood of Patients with Colon Cancer.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Interventional factors influencing natural killer cell immunity in colorectal cancer: a systematic review.Cancer immunology, immunotherapy : CII · 2025Pooled it
- Impact of propofol on gastrointestinal cancer outcomes: A review of cellular behavior, growth, and metastasis.World journal of clinical oncology · 2025Review
- Anesthetic Approaches and Their Impact on Cancer Recurrence and Metastasis: A Comprehensive Review.Cancers · 2024Review
- The Role of Anesthetic Management in Lung Cancer Recurrence and Metastasis: A Comprehensive Review.Journal of clinical medicine · 2024Review
- Influence of Perioperative Anesthesia on Cancer Recurrence: from Basic Science to Clinical Practice.Current oncology reports · 2023Review
- The Effect of Different Anesthetic Techniques on Proliferation, Apoptosis, and Gene Expression in Colon Cancer Cells: A Pilot In Vitro Study.Current issues in molecular biology · 2023Article
- Natural killer cells: a promising immunotherapy for cancer.Journal of translational medicine · 2022Review
- Local anesthetics elicit immune-dependent anticancer effects.Journal for immunotherapy of cancer · 2022Article
- An intravenous anesthetic drug-propofol, influences the biological characteristics of malignant tumors and reshapes the tumor microenvironment: A narrative literature review.Frontiers in pharmacology · 2022Review
- Postoperative Natural Killer Cell Dysfunction: The Prime Suspect in the Case of Metastasis Following Curative Cancer Surgery.International journal of molecular sciences · 2021Review
- Propofol Regulates the TLR4/NF-κB Pathway Through miRNA-155 to Protect Colorectal Cancer Intestinal Barrier.Inflammation · 2021Article
- Propofol postpones colorectal cancer development through circ_0026344/miR-645/Akt/mTOR signal pathway.Open medicine (Warsaw, Poland) · 2021Article
- Anesthesia Techniques and Long-Term Oncological Outcomes.Frontiers in oncology · 2021Review
- Effects of propofol and sevoflurane on tumor killing activity of peripheral blood natural killer cells in patients with gastric cancer.The Journal of international medical research · 2020Article
- Anesthesia Options and the Recurrence of Cancer: What We Know so Far?Local and regional anesthesia · 2020Review
- The protective effect of propofol on ionizing radiation-induced hematopoietic system damage in mice.RSC advances · 2019Article
- Propofol Inhibits the Proliferation, Migration, and Stem-like Properties of Bladder Cancer Mainly by Suppressing the Hedgehog Pathway.Cell transplantationArticle
- Impact of anesthesia and analgesia techniques on glioblastoma progression. A narrative review.Neuro-oncology advancesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND We investigated the effect of propofol on activities and tumor-killing ability of natural killer (NK) cells in patients with colon cancer. MATERIAL AND METHODS Twenty colon cancer patients and 20 healthy subjects were included. Peripheral blood (5 ml) was collected from all patients and healthy subjects. NK cells in peripheral blood were separated by negative screening using immunomagnetic beads. Flow cytometry was used to determine expression of activated receptors, inhibitory receptors, killing effector molecules, and proliferation-associated markers on NK cell surfaces. After in vitro treatment with propofol for 24 h, expression of activated receptors, inhibitory receptors, killing effector molecules, and proliferation-associated markers on NK cell surfaces was examined again. In addition, the tumor-killing effect of NK cells was studied by co-culture with K562 cells or colon cancer SW620 cells at a ratio of 1: 1. RESULTS The number of NK cells in peripheral blood from colon cancer patients was increased compared with healthy subjects, but activities and proliferation ability of the NK cells were decreased. The tumor-killing effect of NK cells isolated from colon cancer patients was decreased. Of note, propofol promoted activation of NK cells from colon cancer patients. In addition, propofol increased expression of tumor-killing effector molecules by NK cells and the proliferation ability of NK cells. Propofol also enhanced the killing effect of NK cells on colon cancer cells. CONCLUSIONS The present study demonstrates that propofol promotes the activity and tumor-killing ability of NK cells in peripheral blood of patients with colon cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.